Novartis to Request Kisqali’s Approval to Treat Premenopausal Women on Basis of Phase 3 Trial

Novartis to Request Kisqali’s Approval to Treat Premenopausal Women on Basis of Phase 3 Trial
Novartis plans to begin work with regulatory authorities to request that Kisqali (ribociclib) be approved as a first-line treatment for premenopausal women with HR-positive, HER2-negative advanced breast cancer. This decision came after a Phase 3 trial demonstrated that Kisqali, in combination with hormone treatment, delayed disease progression or death in these women, compared to hormone

Knowledge is power when living with breast cancer.

Get access to the web’s leading Breast Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *